SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sbpgroup.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
SECOND-GENERATION FLURBIPROFEN PATCH APPROVED FOR MARKETING

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that the Second-Generation Flurbiprofen Patch (trade name: 澤普思®), a national Category 5.1 innovative drug developed by the Group's subsidiary, Beijing Tide Pharmaceutical Co., Ltd. ("**Beijing Tide**"), has received approval for marketing by the China's National Medical Products Administration (NMPA) for the following indications: analgesia and anti-inflammatory treatment for osteoarthritis, shoulder periarthritis, tendinitis and tenosynovitis, peritendinitis, lateral epicondylitis (tennis elbow), muscle pain, and swelling and pain due to trauma. The product has also been granted a 4-year data protection period by the NMPA, which builds a solid barrier to consolidate the Group's leading market position.

China has over 200 million chronic pain patients, with the affected population increasingly trending younger. Osteoarthritis, sports-related injuries, and neck-shoulder-low back pain are not only common among the middle-aged and elderly but are also rising annually among fitness enthusiasts, outdoor sports participants, and sedentary office workers. Topical analgesic patches have emerged as a preferred option for pain management, offering advantages such as localized drug delivery and avoidance of gastrointestinal irritation. However, traditional cataplasms, characterized by their bulky texture and tendency to detach upon sweating, fall short of meeting patients' practical needs during exercise or daily activities, underscoring an urgent need for more advanced solutions.

As an upgrade to the flurbiprofen cataplasms, the second-generation flurbiprofen patch utilizes novel hot-melt adhesive transdermal technology with improvements in materials, processes, and structure. While fully retaining the proven analgesic efficacy of the original product, it further expands the application scenarios of topical patches, offering advantages such as thinner design, stronger adhesion, quicker onset, and unrestricted mobility.

I. Ultra-thin, Lightweight Design – Invisible and Comfortable

The second-generation flurbiprofen patch features a new-generation ultra-thin matrix-type transdermal technology and an upgraded lightweight, low-irritation backing material, with thickness and weight reduced by 56% and 75%, respectively, versus traditional cataplasms. It is virtually imperceptible upon application, virtually invisible under clothing, and suitable for daily commuting, business, and social settings.

II. Bio-inspired Adhesion Technology – Stays Firm Even When Sweating

The Group's proprietary bio-inspired adhesive material system, mimics superior adhesion mechanisms found in nature, maintaining stable adhesive performance under dry, moist and even sweaty conditions. Laboratory tests show no edge lifting under simulated high-intensity exercise conditions (continuous sweating and repeated stretching), making it ideal for running, ball sports, climbing, and other active pursuits.

III. Fast Drug Release – Quick Pain Relief

Using hot-melt pressure-sensitive adhesive technology, the patch creates a strong concentration gradient to accelerate drug release. Experimental data shows that the permeation rate of the second-generation flurbiprofen patch is 13-fold higher than traditional cataplasms. In real use, the active ingredient is rapidly released from the patch, penetrates the stratum corneum and reaches the pain site directly, providing swift pain relief.

At present, the Group has built a leading modern transdermal technology platform and product portfolio in China. For pain management: flurbiprofen cataplasms (trade name: 得百安®) was approved in 2010 and has remained the top brand in the topical analgesic market for many years; lidocaine cataplasms (trade name: 得百寧®) was approved in 2018, addressing the unmet need for external treatment of postherpetic neuralgia. For central nervous system: rivastigmine transdermal patch (trade name: 蘇樂達®) was approved in 2024 for Alzheimer's disease; rotigotine transdermal patch (trade name: 羅菲定®) was approved in 2025 for Parkinson's disease. For respiratory: tulobuterol patch (trade name: 德瑞妥®) was approved in 2025, marking the entry of respiratory disease management into the "patch era". The Group has thus established a comprehensive transdermal patch portfolio covering pain management, CNS, respiratory, and metabolism.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 6 August 2026

As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.